Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.1%
    Check dated 2025-09-09T00:17:15.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new facility names and locations across various regions, as well as updated drug information for Pembrolizumab, Belzutifan, and Lenvatinib. Notably, some previously listed locations and drug information have been removed.
    Difference
    11%
    Check dated 2025-09-01T20:31:57.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.0%
    Check dated 2025-08-18T13:23:42.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-08-11T06:52:56.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The page has been updated to reflect the latest version as v2.16.10, replacing the previous version v2.16.8. Additionally, a service alert regarding planned maintenance has been removed.
    Difference
    0.7%
    Check dated 2025-08-04T02:27:08.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect new site locations and identifiers, with some previous locations and identifiers removed. Notably, the registry identifier has been updated, and the last update date has been changed to a later date.
    Difference
    1%
    Check dated 2025-07-27T22:57:13.000Z thumbnail image

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.